Jean S.-S.PO-REN HSUEH2020-12-182020-12-1820202213-7165https://scholars.lib.ntu.edu.tw/handle/123456789/528125Objectives: To investigate the susceptibility profiles amongst ertapenem-non-susceptible non-carbapenemase-producing Enterobacterales (ETP-NS-non-CPE) isolates. Methods: Minimum inhibitory concentrations (MICs) of 404 ETP-NS-non-CPE isolates collected from different intra-abdominal infection (IAI) sites amongst patients in the Asia-Pacific region during 2008–2014 were determined using the broth microdilution method. The susceptibility results were interpreted according to the MIC breakpoints recommended by the Clinical and Laboratory Standards Institute (CLSI) in 2018. The MICs data of several agents were evaluated based on their published pharmacokinetic/pharmacodynamic (PK/PD) profiles. Results: The majority (>84%) of IAI-ETP-NS-non-CPE isolates – including Escherichia coli (n = 83), Klebsiella pneumoniae (n = 91) and Enterobacter species (n = 210) – were susceptible to imipenem and amikacin. The 193 hepatobiliary ETP-NS-non-CPE isolates exhibited a trend of lower cefepime MIC (?4 mg/L) distribution than those (n = 145) cultured from the peritoneal space (P = 0.058). Amongst the ETP-NS-non-CP Enterobacter isolates, 65.7% displayed a cefepime MIC ? 4 mg/L. In addition, compared with Escherichia coli and Klebsiella pneumoniae isolates, 82.9% and 72.9% of the ETP-NS-non-CP Enterobacter isolates were susceptible to levofloxacin and ciprofloxacin, respectively. Of note, 74.5% and 70.3% of the ETP-NS-non-CP Enterobacter isolates cultured from the hepatobiliary tract and peritoneal space exhibited a ciprofloxacin MIC ? 2 mg/L and ?0.25 mg/L, respectively. Imipenem and amikacin showed good in vitro susceptibility rates against the IAI-ETP-NS-non-CPE isolates. The hepatobiliary ETP-NS-non-CPE displayed lower cefepime MICs than those cultured from the peritoneal space. Additionally, a significant fraction of IAI-ETP-NS-non-CP Enterobacter isolates exhibited ciprofloxacin MIC ? 2 mg/L. Conclusion: Based upon the PK/PD analyses, ciprofloxacin, imipenem and cefepime are probably effective against IAI-ETP-NS-non-CPE isolates. ? 2019 International Society for Antimicrobial ChemotherapyCefepime; Ciprofloxacin; Ertapenem-non-susceptible non-carbapenemase-producing Enterobacterales; Imipenem; Intra-abdominal infection[SDGs]SDG3[SDGs]SDG14amikacin; cefepime; cefoxitin; ceftriaxone; ciprofloxacin; ertapenem; imipenem; levofloxacin; piperacillin plus tazobactam; amikacin; ciprofloxacin; ertapenem; imipenem; abdominal infection; antibiotic resistance; Article; Australia; bacterium isolate; carbapenemase producing Enterobacteriaceae; controlled study; Cronobacter sakazakii; Escherichia coli; Hong Kong; human; Kazakhstan; Klebsiella oxytoca; Klebsiella pneumoniae; Malaysia; minimum inhibitory concentration; New Zealand; nonhuman; Pantoea agglomerans; Philippines; priority journal; Singapore; South Korea; Taiwan; Thailand; Viet Nam; abdominal infection; Asia; classification; clinical trial; drug effect; Enterobacter; Enterobacteriaceae; Enterobacteriaceae infection; health survey; isolation and purification; microbial sensitivity test; microbiology; multicenter study; Pacific islands; Amikacin; Asia; Ciprofloxacin; Drug Resistance, Bacterial; Enterobacter; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Escherichia coli; Humans; Imipenem; Intraabdominal Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Pacific Islands; Population Surveillancejournal article10.1016/j.jgar.2019.10.004316270232-s2.0-85083427754